United States · Funded startup

Who invested in Spark Biomedical

One round we have observed, with the 0 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 26 Oct 2026

$305Kraised across 1 round since 2025, from 1 source

Latest round
Grant, $305KOct 2025
Investors
0
See who backed them

The rounds

  1. Oct 2025
    Grant$305K

    No investor was named in the report.

    Source recorded

Founders and team

From Spark Biomedical's own website and the SEC filings it signed: 7 on the team.

  • Anja KramerChief Executive Officer
  • Daniel PowellChief Executive Officer and Directori
  • Amy GastonVice President, Marketing
  • Tom FutchExecutive Vice President, Growth
  • Ric PetersonChief Financial Officer
  • Alejandro R. CovalinChief Technology Officer and Directori
  • Navid KhodaparastChief Science Officer and Directori

On the board, as filediCarl R. DeeleyTed R. Costopoulos

Also claim to have backed them

These 3 firms list Spark Biomedical as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Exelvest PartnersInvestment firmPer its own site
Pathway to CuresVC firmPer its own site
WAVE VenturesVC firmPer its own site

Quick answers about Spark Biomedical

How much has Spark Biomedical raised?

Spark Biomedical has raised $305K across 1 round since 2025.

When did Spark Biomedical last raise?

Spark Biomedical's most recent round was a Grant of $305K in Oct 2025.

What was Spark Biomedical's biggest round?

Its most recent round, $305K in Oct 2025, is also its largest on record.

What stage is Spark Biomedical at?

Spark Biomedical's latest named round is a Grant, in Oct 2025.

Where is Spark Biomedical based?

Spark Biomedical is based in the United States.

Companies like Spark Biomedical

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.